ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced Jim Daly has joined its Board of Directors. Mr. Daly is a biopharmaceutical executive with 30 years of experience leading U.S. and global businesses.

“Jim brings extensive commercial experience to our Board as we continue our transition to an integrated pharmaceutical company,” said Leslie L. Iversen, Ph.D., Chairman of ACADIA’s Board of Directors. “Over the course of his career, Jim has successfully launched and commercialized major products in multiple therapeutic areas and built market-leading global franchises. His deep knowledge and expertise are welcome as we deliver on our vision of building a leading CNS company dedicated to improving the lives of patients through innovative medicines.”

Mr. Daly previously served as Executive Vice President and Chief Commercial Officer at Incyte Corporationfrom 2012 to 2015. During his tenure, he was instrumental in re-accelerating the launch of Jakafi® and driving sustained growth. Prior to joining Incyte, Mr. Daly worked for Amgen, Inc. for ten years, holding multiple leadership positions. In his last role, Mr. Daly served as Senior Vice President, North AmericaCommercial Operations, Global Marketing and Commercial Development. Previously, he served as Vice President and General Manager of Amgen’s Oncology Business Unit. His teams at Amgen were responsible for the successful launch of many products, including Aranesp®, Neulasta®, Vectibix®, Nplate®, Xgeva® and Prolia®.

Previously, Mr. Daly spent over 16 years with Glaxo Wellcome/GlaxoSmithKline (GSK) where he held roles of increasing responsibility, including Senior Vice President, General Manager, Respiratory and Anti-Infective Business Unit, and led the U.S. launch of Advair®. He currently serves on the Board of Directors of Chimerix Inc. Mr. Daly earned his B.S. in Pharmacy and M.B.A. from the University at Buffalo, The State University of New York. (Original Source)

Shares of Acadia closed last Friday at $28.04, down $0.69 or -2.40%. ACAD has a 1-year high of $51.99 and a 1-year low of $27.51. The stock’s 50-day moving average is $34.86 and its 200-day moving average is $38.24.

On the ratings front, Acadia has been the subject of a number of recent research reports. In a report issued on December 15, Leerink Swann analyst Paul Matteis maintained a Buy rating on ACAD, with a price target of $47, which represents a potential upside of 67.6% from where the stock is currently trading. Separately, on November 6, Piper Jaffray’s Charles Duncan downgraded the stock to Hold and has a price target of $39.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Paul Matteis and Charles Duncan have a total average return of -30.8% and -1.3% respectively. Matteis has a success rate of 7.4% and is ranked #3555 out of 3610 analysts, while Duncan has a success rate of 37.9% and is ranked #2582.

ACADIA Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the business of development and commercialization of small molecule drugs for the treatment of central nervous system disorders.